|
|
|
DOPAMINE BIOSYNTHETIC PATHWAY (PW:0000802)
DescriptionThe synthesis and release of catecholamines epinephrine, norepinephrine and dopamine are triggered by various but distinct stresses. Dopamine acts as a neurotransmitter and a neurohormone. It signals via various dopaminergic receptors, G-protein coupled receptors (GPCR) which couple to distinct G alpha subunits of heterotrimeric G proteins. Dopamine synthesis takes place in cholinergic neurons; it is a precursor for both norepinephrine and epinephrine but its roles are distinct. It functions mainly to inhibit the release of prolactin from the pituitary gland, it increases heart rate and blood pressure and is involved in metabolic control. Acting through a family of at least 5 receptors grouped into two subfamilies, it has important roles in cognition, motor control, mood and reward systems. Catecholamine synthesis and the activities of its enzymes are regulated by neuronal and humoral mechanisms. The precursor of all catecholamines is L-tyrosine which can be derived from the diet or from the hydroxylation of L-phenylalanine. Tyrosine hydroxylase (Th), an iron-containing, biopterin-dependent soluble enzyme catalyzes the conversion of tyrosine to dihydroxy-L-phenylalanine (L-DOPA) in the rate-limiting step of the reaction. The cofactor tetrahydrobioterin (BH4) is used in the reaction and the resulting dihydrobiopterin (BH2) is reconverted to BH4 by dihydropteridine reductase. Tetrahydrobiopterin can also be synthesized de novo from the purine nucleotide GTP. The short term control of TH activity is due to product(s)-based inhibitory feedback and activation by phosphorylation; several kinases and phosphatases have been implicated in modulating the activity of the enzyme. Long term control involves regulation of transcription, stability and in humans, alternative splicing. L-DOPA is converted to dopamine (DA) by the pyridoxal phosphate-dependent aromatic L-amino acid decarboxylase (Ddc). Both Th and Ddc interact with vesicle protein Slc182a, which couples DA synthesis with transport into vesicles. To see the ontology report for GViewer, annotations and download, click here[click to see the ontology report for related GO term - GO:0042416 and entry at Reactome - REACT_15442.1] ...(less)
|
Pathway Diagram:
|
|
|
Genes in Pathway:
dopamine biosynthetic pathway
|
| G |
Ddc |
dopa decarboxylase (aromatic L-amino acid decarboxylase) |
|
|
ISS |
14 |
92,698,636 |
92,788,635 |
RGD:4139904 |
RGD |
| G |
Qdpr |
quinoid dihydropteridine reductase |
|
|
ISS |
14 |
70,741,998 |
70,755,600 |
RGD:4139904 |
RGD |
| G |
Slc18a2 |
solute carrier family 18 (vesicular monoamine), member 2 |
|
|
IDA |
1 |
265,789,917 |
265,824,551 |
RGD:5128868 |
RGD |
| G |
Th |
tyrosine hydroxylase |
|
|
ISS |
1 |
203,164,253 |
203,171,506 |
RGD:4139904 |
RGD |
|
|
|
Pathway Gene Annotations |
|
Disease Annotations Associated with Genes in the dopamine biosynthetic pathway
|
|
|
|
| Ddc | Aromatic amino acid decarboxylase deficiency , Dyskinesia, Drug-Induced , Hyperinsulinism , Hypertension, Portal , Kidney Failure, Chronic , Liver Cirrhosis, Experimental , Metabolism, Inborn Errors , Nephrotic Syndrome , Parkinson Disease | | Qdpr | Diabetes Mellitus, Experimental , HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C , Hypertension , Lead Poisoning , Phenylketonurias , Status Epilepticus | | Slc18a2 | Depressive Disorder , Diabetes Mellitus, Type 1 , Machado-Joseph Disease , Neurotoxicity Syndromes , Parkinson Disease , Substance-Related Disorders | | Th | Brain Injuries , Brain Ischemia , Contusions , Diabetes Mellitus, Experimental , Epilepsy , Heart Failure , Hyperprolactinemia , Hypertension , Hypertension, Portal , Hypoglycemia , Infarction, Middle Cerebral Artery , Intellectual Disability , Liver Cirrhosis, Experimental , Machado-Joseph Disease , Myocardial Infarction , Obesity , Parkinson Disease , Parkinsonian Disorders , Polycystic Ovary Syndrome , Reperfusion Injury , Segawa syndrome, autosomal recessive , stress related behavior , Substance Withdrawal Syndrome , Uremia | |
| stress related behavior | Th | | Epilepsy | Th | | Intellectual Disability | Th | | Metabolism, Inborn Errors | Ddc | | Phenylketonurias | Qdpr | | Hyperprolactinemia | Th | | Obesity | Th | | Hypoglycemia | Th | | Nephrotic Syndrome | Ddc | | Kidney Failure, Chronic | Ddc | | Diabetes Mellitus, Type 1 | Slc18a2 | | Hypertension | Th , Qdpr | | Parkinson Disease | Ddc , Slc18a2 , Th | | Parkinsonian Disorders | Th | | Polycystic Ovary Syndrome | Th | | Machado-Joseph Disease | Slc18a2 , Th | | Aromatic amino acid decarboxylase deficiency | Ddc | | Segawa syndrome, autosomal recessive | Th | | Hypertension, Portal | Ddc , Th | | Hyperinsulinism | Ddc | | Substance Withdrawal Syndrome | Th | | Neurotoxicity Syndromes | Slc18a2 | | Brain Injuries | Th | | Substance-Related Disorders | Slc18a2 | | Brain Ischemia | Th | | Contusions | Th | | Depressive Disorder | Slc18a2 | | Diabetes Mellitus, Experimental | Qdpr , Th | | Dyskinesia, Drug-Induced | Ddc | | Heart Failure | Th | | Uremia | Th | | Lead Poisoning | Qdpr | | Liver Cirrhosis, Experimental | Ddc , Th | | Myocardial Infarction | Th | | Status Epilepticus | Qdpr | | Reperfusion Injury | Th | | Infarction, Middle Cerebral Artery | Th | | HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C | Qdpr | |
|